Stocktoria

Xeris Biopharma Holdings, Inc. XERS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-06-21

Xeris Biopharma Holdings, Inc. statistics & valuation

Market cap$1.2B
P / S4.1×
P / B87.0×
Net margin0.2%
Return on equity4.0%
Net debt$109.3M
Net debt / EBITDA4.2×
Enterprise value USD$1.3B
EV / EBITDA49.6×
Earnings yield EBIT/EV1.9%
Return on capital9.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-446.00% -247.50% -85.90% -38.00% -27.00% 0.20% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-408.80% -232.20% -74.30% -26.80% -16.60% 8.50% 202020212022202320242025
Return on equity (%)
-270.00% -128.90% -209.50% 4.00% 202020212022202320242025
Shares outstanding
59.6M 124.9M 136.3M 138.1M 149.4M 172.7M 202020212022202320242025
Net debt ($)
$49.4M $20.8M $65.1M $123.5M $160.5M $109.3M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-57.30% -40.30% -27.50% -19.30% -17.00% 0.10% 202020212022202320242025
Free cash flow margin (%)
-396.10% -194.80% 202020212022202320242025
Debt / equity (×)
2.58× 0.92× 4.14× 16.10× 202020212022202320242025
EPS ($)
-$1.55 -$0.70 -$0.45 -$0.37 $0.00 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin8.5%-16.6%-26.8%-74.3%-232.2%-408.8%
Net margin0.2%-27.0%-38.0%-85.9%-247.5%-446.0%
FCF margin————-194.8%-396.1%
Return on assets0.1%-17.0%-19.3%-27.5%-40.3%-57.3%
Return on equity4.0%185.2%917.9%-209.5%-128.9%-270.0%
Debt / equity16.10×-7.84×-28.15×4.14×0.92×2.58×
Current ratio2.191.671.642.541.805.40

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.